Marco Meglio

For those with an intermediate level of tau and clinical symptoms of Alzheimer disease, treatment with donanemab resulted in a 39% lower risk of progressing to the next stage of disease relative to placebo.

The chief scientific officer at Alzheon discussed new, positive 12-month findings on ALZ-801, an investigational agent in development for patients with early-stage Alzheimer disease.

Total disease burden, measured by the Facioscapulohumeral Muscular Dystrophy Health Index, was reduced by 19% over a 24-week period on recombinant human growth hormone.

Higher adherence to Mediterranean Diet Adherence Screener independently predicted 20% lower risk for cognitive impairment among patients with MS.

Although it has the same ingredients as previously approved Xyrem, extended-release sodium oxybate is a medication taken once-nightly instead of twice-nightly.

A statistically significantly higher proportion of patients, both with and without predose aura, achieved 2-hour relief of the most bothersome symptom with zavegepant.

In a subgroup of individuals with Huntington disease with high baseline C4a/C4 levels, treatment with ANX005 resulted in significant improvement in composite Unified Huntington’s Disease Rating Scale across all timepoints.

Kimberly O’Neill, MD, pediatric neuroimmunology fellow at NYU Langone, discussed her presentation at the 2023 AAN Annual Meeting focused on cognitive similarities between pediatric and adult MS.

Q-Motor, an objective measure of motor function, showed robust beneficial effects for individuals treated with pridopidine in PROOF-HD at various time points.

After 66 weeks of treatment, patients on eplontersen showed sustained reduction in TTR concentration, halted progression of neuropathy impairment, and improved quality of life.

In comparison with placebo, atogepant 30 mg twice daily and 60 mg once daily resulted in greater reductions in monthly migraine days, as well as proportion of patients with at least 50% reduction in 3-month average of MMDs.

A greater proportion of patients on ubrogepant reported absence of moderate-to-severe intensity headache within 48 hours, ability to function normally, and absence of headache of any intensity.

The president elect of the Association of University Professors of Neurology provided thoughts on the promising concepts in neurology and the reasons young medical professionals should join the field.

In single-ascending dose and multiple-ascending dose studies, no clinically meaningful changes were noted in hematology, chemistry, vital signs, or electrocardiogram parameters.

After 192 weeks, more than 90% of patients on ocrelizumab had no relapses and slightly more than 80% had no 24-week confirmed disability progression.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Angela Genge, MD, FRCPC. [LISTEN TIME: 13 minutes]

Branded as Qalsody, the FDA has granted approval to Biogen and Ionis' tofersen, making it the fourth therapy approved for ALS and the first for SOD1-associated disease.

No significant differences between P2B001 and Prami-ER were seen in total UPDRS responders, UPDRS Part II, and UPDRS Part III scores among those with Parkinson disease.

Adverse events like dyskinesia, ON and OFF phenomenon, and falls, were all higher during the 4-week optimization phase than the 8-week maintenance phase.

FDA-approved for adults with generalized myasthenia gravis in 2016, eculizumab continued to show promising efficacy and safety responses in adolescents with the disease, regardless of on concomitant use of IVIG.

After 228 weeks of treatment, annualized relapse rates favored twice-daily 75 mg dosing of evobrutinib vs once-daily.

The majority of treatment-emergent adverse events from IPX203 were mild or moderate in nature, and occurred within the first 90 days of treatment.

Treatment with ALZ-801, an investigational agent in development for Alzheimer disease, resulted in more than 40% reduction in plasma p-tau181 at the end of the 12-month analysis.

There were no observed tolebrutinib dose effect for treatment-emergent adverse events in the double-blind portion, as well as no new safety signals seen for those who crossed over in the open-label extension.

Rozanolixizumab has shown promising effects as a potential treatment for myasthenia gravis, as explained by high response rates on MG Activities of Daily Living and other measures.

After 90 days, investigators found that tenecteplase was not associated with improvements in functional outcome, nor did it differ from placebo on mortality.

NMOSD-related optic neuritis represented the strongest predictive risk factor of failure to attain visual recovery of at least 0.3 logMAR, with an odds ratio of 10.47.

Greater cumulative exposure to HbA1c concentrations in the range of 6% to less than 8%, targets proposed by most geriatrics’ guidelines for healthier older people, were associated with lower hazard of dementia.

After showing promise in a phase 2 assessment, Taisho Pharmaceutical’s TS-142 will be assessed in a long-term study of 300 patients with the sleeping disorder.

Collectively, the results suggested that multiple sclerosis and migraine may co-occur because they share several genetic variants, rather than migraine causing MS.